This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Medical Ethics  • Cardiovascular System  • Quality of Care  • Patient Safety/ Medical Error  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Hematology/ Hematologic Malignancies  • Anemias  • Hematology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We agree with the Editorial by Drs Fergusson and McIntyre¹ that an artificial blood substitute must be "safe, effective, and universally available." Yet we find that their affirmation that the US blood supply is "adequate and safe" problematic.

According to the America's Blood Centers Web site,² only 53 of their 93 associated centers have a supply for 3 days or more (52% of their network blood supply). Infectious diseases threats to the blood supply (such as hepatitis B and C, HIV, West Nile virus, and variant Creutzfeldt-Jakob disease) that have led to increased complexity of donor screening,^2-3 the possibility of national emergencies, and circumstances in which stored blood is not acceptable or viable (eg, cultural/religious impediments, cross-matching incompatibility), as well as adverse immunoinflammatory effects of stored blood transfusions despite leukoreduction,⁴ require that risks potentially associated with artificial blood substitutes be balanced against its potential benefits for specific . . . [Full Text of this Article]

Angela Sauaia, MD, PhD
angela.sauaia@uchsc.edu

Ernest E. Moore, MD; Anirban Banerjee, PhD
University of Colorado Denver School of Medicine

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death: A Meta-analysis
Charles Natanson, Steven J. Kern, Peter Lurie, Steven M. Banks, and Sidney M. Wolfe
JAMA. 2008;299(19):2304-2312.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Lewis J. Levien, Richard E. Hodgson, and Michael F. M. James
JAMA. 2008;300(11):1295.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Peter E. Keipert, Christina Olofsson, and Robert M. Winslow
JAMA. 2008;300(11):1295-1296.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Roger J. Lewis and Norman Fost
JAMA. 2008;300(11):1296.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Aryeh Shander, Mazyar Javidroozi, and Gary Thompson
JAMA. 2008;300(11):1296-1297.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Babak Sarani and Vicente Gracias
JAMA. 2008;300(11):1297-1298.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply
Charles Natanson, Peter Lurie, and Sidney M. Wolfe
JAMA. 2008;300(11):1298-1299.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply
Dean Fergusson and Lauralyn McIntyre
JAMA. 2008;300(11):1299.
EXTRACT | FULL TEXT